CNVVY (ConvaTec Group) LT-Debt-to-Total-Asset : 0.38 (As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is ConvaTec Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ConvaTec Group's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.38.

ConvaTec Group's long-term debt to total assets ratio declined from Jun. 2023 (0.39) to Jun. 2024 (0.38). It may suggest that ConvaTec Group is progressively becoming less dependent on debt to grow their business.

ConvaTec Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for ConvaTec Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ConvaTec Group LT-Debt-to-Total-Asset Chart

ConvaTec Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.42

0.38

0.35

0.36

0.35

ConvaTec Group Semi-Annual Data
	Dec13	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.35	0.36	0.39	0.35	0.38

ConvaTec Group LT-Debt-to-Total-Asset Calculation

ConvaTec Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1291.7	/	3713.7
	=	0.35

ConvaTec Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	1391	/	3624.3
	=	0.38

ConvaTec Group (OTCPK:CNVVY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ConvaTec Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of ConvaTec Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ConvaTec Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ConvaTec Group PLC (OTCPK:CNVVY) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

CNVVF:USA CTECl:UK CTEC:UK 2CV:Germany

Address

20 Eastbourne Terrace, 7th Floor, Paddington, London, GBR, W2 6LG

Website

https://www.convatecgroup.com

Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue.